Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Merkel Cell Carcinoma Market to Grow Rapidly at a CAGR of 8.7% During the Study Period (2020-2034) | DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

09 Apr, 2025, 21:31 GMT

Share this article

Share toX

Share this article

Share toX

The Merkel cell carcinoma market is poised for steady growth, with a strong CAGR projected from 2024 to 2034. This expansion across the 7MM will be driven by the launch of innovative therapies, including IFx-2.0, NIDLEGY, and ITI-3000.

LAS VEGAS, April 9, 2025 /PRNewswire/ -- DelveInsight's Merkel Cell Carcinoma Market Insights report includes a comprehensive understanding of current treatment practices, Merkel cell carcinoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Takeaways from the Merkel Cell Carcinoma Market Report

  • According to DelveInsight's analysis, the market size for Merkel cell carcinoma was found to be USD 411 million in the 7MM in 2023.
  • According to estimates, among the currently marketed drugs, BAVENCIO (avelumab) as first-line therapy held the largest market share, generating approximately USD 290 million in revenue across the 7MM in 2023.
  • According to DelveInsight's estimates, in 2023, there were approximately 9K incident cases of MCC in the 7MM. Of these, the United States accounted for 37% of the cases.
  • Leading Merkel cell carcinoma companies developing emerging therapies, such as TuHURA Biosciences, Philogen, Immunomic Therapeutics, Phio Pharmaceuticals, AgonOx, Kymera Therapeutics, Merus N.V., and others are developing novel Merkel cell carcinoma drugs that can be available in the Merkel cell carcinoma market in the coming years. 
  • The promising Merkel cell carcinoma therapies in the pipeline include IFx-2.0, NIDLEGY (L19-IL2/L19-TNF), ITI 3000, PH 762, KT 253, MCLA 145, and others.

Discover which therapies are expected to grab the major Merkel cell carcinoma market share @ Merkel Cell Carcinoma Market Report

Merkel Cell Carcinoma Overview

Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer that originates from Merkel cells, which are neuroendocrine cells involved in touch sensation. While its exact causes are not completely understood, several risk factors have been identified, including prolonged exposure to ultraviolet (UV) radiation, advanced age, and a weakened immune system; additionally, infection with the Merkel Cell Polyomavirus (MCPyV) is associated with many cases of MCC. 

Clinically, MCC often presents as a rapidly growing, firm, and painless nodule that may appear red, violet, or flesh-colored, typically on sun-exposed areas such as the head, neck, or extremities. Diagnosis usually begins with a detailed physical examination and imaging studies to assess the extent of the lesion, but a definitive diagnosis is made through a biopsy followed by histopathological and immunohistochemical analyses, which help distinguish MCC from other similar skin tumors.

Merkel Cell Carcinoma Epidemiology Segmentation

The Merkel cell carcinoma epidemiology section provides insights into the historical and current Merkel cell carcinoma patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The Merkel cell carcinoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Incident Cases of MCC 
  • Gender-specific Incident Cases of MCC 
  • Stage-specific Incident Cases of MCC 
  • Etiology-specific Incident Cases of MCC 
  • Total Metastatic Cases of MCC 

Merkel Cell Carcinoma Treatment Market 

Treatment for localized Merkel cell carcinoma typically involves surgery and radiation, while advanced cases often require systemic therapies such as immune checkpoint inhibitors like avelumab. Chemotherapy provides limited long-term benefits. Wide local excision is the primary approach for localized MCC, often accompanied by a sentinel lymph node biopsy to assess disease spread. However, in advanced stages, surgery becomes less effective as systemic progression takes over, emphasizing the need for improved treatments due to MCC's rarity and high recurrence risk. 

Chemotherapy, once a mainstay for advanced MCC, now plays a diminished role due to its limited long-term efficacy. Agents like etoposide and carboplatin may temporarily shrink tumors, but high relapse rates and significant side effects make them less favorable. Cytotoxic chemotherapy works by damaging DNA or disrupting cell division in rapidly proliferating cells, but while it has shown effectiveness in metastatic MCC, its impact on healthy cells leads to considerable adverse effects. 

Currently, several approved therapies focus on immune modulation. Key treatments include BAVENCIO, a monoclonal antibody developed by Merck KGaA; KEYTRUDA (pembrolizumab), a PD-1 inhibitor from Merck; and ZYNYZ (retifanlimab-dlwr), a PD-1 inhibitor co-developed by Incyte Corporation and MacroGenics.

To know more about Merkel cell carcinoma treatment guidelines, visit @ Merkel Cell Carcinoma Management 

Merkel Cell Carcinoma Pipeline Therapies and Key Companies

  • IFx-2.0: TuHURA Biosciences
  • NIDLEGY (L19-IL2/L19-TNF): Philogen
  • ITI 3000: Immunomic Therapeutics
  • PH 762: Phio Pharmaceuticals/AgonOx
  • KT 253: Kymera Therapeutics
  • MCLA 145: Merus N.V.

Discover more about Merkel cell carcinoma drugs in development @ Merkel Cell Carcinoma Clinical Trials 

Merkel Cell Carcinoma Market Dynamics

The Merkel cell carcinoma market dynamics are expected to change in the coming years. With the increasing awareness and early detection of Merkel cell carcinoma, healthcare providers are now more proactive in diagnosing the disease, which in turn fuels demand for effective, targeted treatments. Recent regulatory approvals of novel therapies, such as checkpoint inhibitors, have not only improved patient outcomes but have also spurred further research and development investments from pharmaceutical companies. Additionally, the high unmet medical need in this niche area, coupled with supportive government policies and funding initiatives, continues to propel the growth and expansion of the Merkel cell carcinoma therapeutic market.

Furthermore, potential therapies are being investigated for the treatment of Merkel cell carcinoma, and it is safe to predict that the treatment space will significantly impact the Merkel cell carcinoma market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the Merkel cell carcinoma market in the 7MM.

However several factors may impede the growth of the Merkel cell carcinoma market. One major challenge is the rarity of the disease, which limits the availability of clinical trial participants and reduces incentives for pharmaceutical companies to invest in research. Additionally, the high costs of immunotherapies—the primary treatment option—pose affordability issues, leading to restricted patient access, especially in regions with limited healthcare coverage. Regulatory hurdles also slow the approval of novel therapies, as MCC lacks well-established treatment guidelines beyond immunotherapy. Furthermore, low disease awareness among healthcare providers and patients often results in delayed diagnosis, and worsening patient outcomes.

Moreover, Merkel cell carcinoma treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the Merkel cell carcinoma market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the Merkel cell carcinoma market growth.

Merkel Cell Carcinoma Market Report Metrics

Details

Study Period

2020–2034

Coverage

7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Merkel Cell Carcinoma Market CAGR

8.7 %

Merkel Cell Carcinoma Market Size in 2023

USD 411 Billion

Key Merkel Cell Carcinoma Companies

TuHURA Biosciences, Philogen, Immunomic Therapeutics, Phio Pharmaceuticals, AgonOx, Kymera Therapeutics, Merus N.V., and others

Key Pipeline Merkel Cell Carcinoma Therapies

IFx-2.0, NIDLEGY (L19-IL2/L19-TNF), ITI 3000, PH 762, KT 253, MCLA 145, and others

Scope of the Merkel Cell Carcinoma Market Report

  • Therapeutic Assessment: Merkel Cell Carcinoma current marketed and emerging therapies
  • Merkel Cell Carcinoma Market Dynamics: Key Market Forecast Assumptions of Emerging Merkel Cell Carcinoma Drugs and Market Outlook
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, Merkel Cell Carcinoma Market Access and Reimbursement

Download the report to understand which factors are driving Merkel cell carcinoma market trends @ Merkel Cell Carcinoma Market Trends

Table of Contents

1

Key Insights

2

Report Introduction

3

MCC Market Overview at a Glance

3.1

Market Share (%) Distribution of MCC by Therapies in the 7MM in 2020

3.2

Market Share (%) Distribution of MCC by Therapies in the 7MM in 2034

4

Executive Summary

5

Key Events

6

Disease Background and Overview

6.1

Introduction

6.2

Anatomy

6.3

Histology of MCC

6.4

Signs and Symptoms

6.5

Risk Factors

6.6

Types of MCC

6.7

Pathophysiology of MCC

6.8

Staging of MCC

6.9

Diagnosis

6.9.1

Differential Diagnosis of MCC

6.9.2

Diagnostic Algorithm

6.9.3

Diagnostic Guidelines and Recommendations for MCC

6.10

Treatment

6.10.1

Follow-up and Recurrence

6.10.2

Treatment Algorithm

6.10.3

Treatment Guidelines and Recommendations for MCC

7

Epidemiology and Market Methodology

8

Epidemiology and Patient Population

8.1

Key Findings

8.2

Assumptions and Rationale: 7MM

8.2.1

Total Incident Cases of MCC

8.2.2

Gender-specific Incident Cases of MCC

8.2.3

Stage-specific Incident Cases of MCC

8.2.4

Etiology-specific Incident Cases of MCC

8.2.5

Progression Rate of MCC

8.3

Total Incident Cases of MCC in the 7MM

8.4

The United States

8.4.1

Total Incident Cases of MCC in the US

8.4.2

Gender-specific Incident Cases of MCC in the US

8.4.3

Stage-specific Incident Cases of MCC in the US

8.4.4

Etiology-specific Incident Cases of MCC in the US

8.4.5

Total Metastatic Cases of MCC in the US

8.5

EU4 and the UK

8.5.1

Total Incident Cases of MCC in EU4 and the UK

8.5.2

Gender-specific Incident Cases of MCC in EU4 and the UK

8.5.3

Stage-specific Incident Cases of MCC in EU4 and the UK

8.5.4

Etiology-specific Incident Cases of MCC in EU4 and the UK

8.5.5

Total Metastatic Cases of MCC in EU4 and the UK

8.6

Japan

8.6.1

Total Incident Cases of MCC in Japan

8.6.2

Gender-specific Incident Cases of MCC in Japan

8.6.3

Stage-specific Incident Cases of MCC in Japan

8.6.4

Etiology-specific Incident Cases of MCC in Japan

8.6.5

Total Metastatic Cases of MCC in Japan

9

Patient Journey

10

Marketed Therapies

10.1

Key Cross Competition

10.2

BAVENCIO (avelumab): Merck KGaA (EMD Serono)

10.2.1

Product Description

10.2.2

Regulatory Milestone

10.2.3

Other Developmental Activities

10.2.4

Clinical Trials Information

10.2.5

Safety and Efficacy

10.3

ZYNYZ (retifanlimab-dlwr): Incyte Corporation/MacroGenics

10.3.1

Product Description

10.3.2

Regulatory Milestone

10.3.3

Other Developmental Activities

10.3.4

Clinical Trials Information

10.3.5

Safety and Efficacy

10.4

KEYTRUDA (pembrolizumab): Merck

10.4.1

Product Description

10.4.2

Regulatory Milestone

10.4.3

Other Developmental Activities

10.4.4

Clinical Trials Information

10.4.5

Safety and Efficacy

To be continued in the report...

11

Emerging Drug Profiles

11.1

Key Cross Competition of Emerging Drugs

11.2

IFx-2.0: TuHURA Biosciences

11.2.1

Drug Description

11.2.2

Other Developmental Activities

11.2.3

Clinical Trials Information

11.2.4

Safety and Efficacy

11.2.5

Analysts' View

11.3

NIDLEGY (L19-IL2/L19-TNF): Philogen

11.3.1

Drug Description

11.3.2

Other Developmental Activities

11.3.3

Clinical Trials Information

11.3.4

Analysts' View 

11.4

ITI 3000: Immunomic Therapeutics

11.4.1

Drug Description

11.4.2

Other Developmental Activities

11.4.3

Clinical Trials Information

11.4.4

Safety and Efficacy

11.4.5

Analysts' View 

11.5

PH 762: Phio Pharmaceuticals/AgonOx

11.5.1

Drug Description

11.5.2

Other Developmental Activities

11.5.3

Clinical Trials Information

11.5.4

Safety and Efficacy

11.5.5

Analysts' View 

11.6

KT 253: Kymera Therapeutics

11.6.1

Drug Description

11.6.2

Other Developmental Activities

11.6.3

Clinical Trials Information

11.6.4

Safety and Efficacy

11.6.5

Analysts' View

11.7

MCLA 145: Merus N.V.

11.7.1

Drug Description

11.7.2

Other Developmental Activities

11.7.3

Clinical Trials Information

11.7.4

Safety and Efficacy

11.7.5

Analysts' View

To be continued in the report...

12

MCC: Market Analysis

12.1

Key Findings

12.2

Key Market Forecast Assumptions

12.2.1

Cost Assumptions and Rebates

12.2.2

Pricing Trends

12.2.3

Analogue Assessment

12.2.4

Launch Year and Therapy Uptake

12.3

Market Outlook

12.4

Total Market Size of MCC in the 7MM

12.5

Market Size of MCC by Therapies in the 7MM

12.6

Market Size of MCC in the United States

12.6.1

Total Market of MCC

12.6.2

Market Size of MCC by Therapies in the United States

12.7

Market Size of MCC in EU4 and the UK

12.7.1

Total Market Size of MCC

12.7.2

Market Size of MCC by Therapies in EU4 and the UK

12.8

Market Size of MCC in Japan

12.8.1

Total Market Size of MCC

12.8.2

Market Size of MCC by Therapies in Japan

13

Key Opinion Leaders' Views

14

Unmet Needs

15

SWOT Analysis

16

Market Access and Reimbursement

16.1

The United States

16.1.1

Center for Medicare and Medicaid Services (CMS)

16.2

In EU4 and the UK

16.2.1

Germany

16.2.2

France

16.2.3

Italy

16.2.4

Spain

16.2.5

The United Kingdom

16.3

Japan

16.3.1

MHLW

17

Appendix

17.1

Acronyms and Abbreviations

17.2

Bibliography

17.3

Report Methodology

18

DelveInsight Capabilities

19

Disclaimer

20

About DelveInsight

Related Reports

Merkel Cell Carcinoma Epidemiology Forecast

Merkel Cell Carcinoma Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Merkel cell carcinoma epidemiology trends.

Merkel Cell Carcinoma Pipeline

Merkel Cell Carcinoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Merkel cell carcinoma companies, including ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos therapeutics, Incyte corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, Sensei Biotherapeutics, among others.

Metastatic Merkel Cell Carcinoma Market

Metastatic Merkel Cell Carcinoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic Merkel cell carcinoma companies, including Incyte Corporation, Merck, Pfizer, Millennium Pharmaceuticals Inc., Novartis, Exelixis, Bristol-Myers Squibb, EMD Serono, among others.

Metastatic Merkel Cell Carcinoma Pipeline

Metastatic Merkel Cell Carcinoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic Merkel cell carcinoma companies, including Incyte Corporation, Transgene, Ocellaris Pharma, Roche, Exelixis, Sensei Biotherapeutics, Checkmate Pharmaceuticals, SOTIO Biotech, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

Modal title

Also from this source

HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020-2034) | DelveInsight

HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020-2034) | DelveInsight

DelveInsight's HER2+ Gastric Cancer (including GEJ) Market report includes a comprehensive understanding of current treatment practices, emerging...

Friedreich's Ataxia Market Poised for Rapid Expansion During the Forecast Period (2025-2034) as Drug Pipeline Gains Momentum | DelveInsight

Friedreich's Ataxia Market Poised for Rapid Expansion During the Forecast Period (2025-2034) as Drug Pipeline Gains Momentum | DelveInsight

DelveInsight's Friedreich's Ataxia Market Insights report includes a comprehensive understanding of current treatment practices, Friedreich's ataxia...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.